Novel compounds for treatment, alleviation or prevention of disorders associated with tau aggregates

A compound and protein aggregate technology, applied in organic chemistry, drug combination, nervous system diseases, etc.

Pending Publication Date: 2021-09-28
AC IMMUNE SA
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, only one kinase inhibitor, nilotinib, has been tested in clinical trials so far

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel compounds for treatment, alleviation or prevention of disorders associated with tau aggregates
  • Novel compounds for treatment, alleviation or prevention of disorders associated with tau aggregates
  • Novel compounds for treatment, alleviation or prevention of disorders associated with tau aggregates

Examples

Experimental program
Comparison scheme
Effect test

preparation example 1

[0133]

[0134] Step A

[0135] To a solution of 4-fluorophenylhydrazine (1 g, 7.9 mmol) and tert-butyl 4-oxopiperidine-1-carboxylate (1.2 g, 8.3 mmol) in 1,4-dioxane (10 mL) , add concentrated H at ice bath temperature 2 SO 4 (1 mL). The reaction mixture was then heated at 110°C for 3 hours. The reaction mixture was cooled to room temperature and the precipitate was filtered off. The solid was dissolved in water, basified with NaOH solution and extracted with DCM (dichloromethane). The organic phase was separated and washed with Na 2 SO 4 Drying and removal of solvent gave the title compound (950 mg, 59%) as a light yellow solid.

[0136]

[0137] Step B

[0138] To a solution of the title compound from Step A above (0.95 g, 4.77 mmol) in THF (tetrahydrofuran) was added di-tert-butyl dicarbonate (Boc 2 (0) (1.5 g), and the mixture was stirred overnight. After thin layer chromatography (TLC) confirmed the completion of the reaction, the solvent was removed...

preparation example 2

[0149]

[0150] Step A

[0151]Add 3-(fluorophenyl)hydrazine (1 g, 6.1 mmol) and tert-butyl 4-oxopiperidine-1-carboxylate (1.2 g, 6.1 mmol) in 1,4-dioxane (10 mL) solution, add concentrated H at 0°C 2 SO 4 (1 mL). The reaction mixture was then warmed to 25°C and heated at 110°C for 3 hours. The reaction mixture was cooled to room temperature, and the precipitate was filtered off. The solid was dissolved in water, basified with NaOH solution and extracted with dichloromethane. The organic phase was separated and washed with Na 2 SO 4 Drying and removal of solvent gave a mixture of regioisomers (0.65 g, 56%) as a light yellow solid.

[0152]

[0153] Step B

[0154] To a solution of the regioisomer mixture (0.65 g, 3.15 mmol) in THF was added di-tert-butyl dicarbonate (0.757 g, 3.47 mmol), and the mixture was stirred for 12 hours. After completion of the reaction (monitored by TLC), the solvent was concentrated under reduced pressure to obtain the crude produc...

preparation example 3

[0169]

[0170] Step A

[0171] Add (2-chloro-3-fluorophenyl)hydrazine (10g, 62.5mmol) and tert-butyl 4-oxopiperidine-1-carboxylate (12g, 62.5mmol) in 1,4-dioxane at 0°C (100 mL) was added concentrated H 2 SO 4 (10 mL). The reaction mixture was then warmed to 25°C and heated at 110°C for 3 hours. The reaction mixture was cooled to room temperature, and the precipitate was filtered off. The solid was dissolved in water, basified with NaOH solution and extracted with dichloromethane. The organic phase was separated and washed with Na 2 SO 4 Drying and removal of solvent gave the title compound (10 g, 72%) as a light yellow solid.

[0172]

[0173] Step B

[0174] To a solution of the title compound from Step A above (10 g, 44.5 mmol) in THF (100 mL) was added di-tert-butyl dicarbonate (10.5 g, 46.5 mmol), and the mixture was stirred for 12 hours. After completion of the reaction (monitored by TLC), the solvent was concentrated under reduced pressure to give c...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
chiral purityaaaaaaaaaa
Login to view more

Abstract

The present invention relates to novel compounds that can be employed in the treatment, alleviation or prevention of a group of disorders and abnormalities associated with Tau (Tubulin associated unit) protein aggregates including, but not limited to, Neurofibrillary Tangles (NFTs), such as Alzheimer's disease (AD).

Description

technical field [0001] The present invention relates to conditions and abnormalities (including but not limited to neurofibrillary tangles (NFT), such as Alzheimer's disease (AD) that can be used to treat, alleviate or prevent Tau (tubulin-associated unit) protein aggregates. )) new compounds. Background technique [0002] Many diseases of aging are based on or are associated with the extracellular or intracellular deposition of amyloid or amyloid-like proteins which contribute to the pathogenesis as well as the progression of the disease. The most characterized amyloid protein that forms extracellular aggregates is amyloid beta protein (Aβ). Other examples of amyloid proteins that form extracellular aggregates are prions, ATTR (transthyretin) or ADan (ADanPP). Amyloid-like proteins that primarily form intracellular aggregates include, but are not limited to, Tau, α-synuclein, TAR DNA binding protein 43 (TDP-43), and huntingtin (htt). Diseases involving Tau aggregates are...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/5377A61P25/28A61K45/06A61P25/00
CPCA61K31/5377A61P25/00A61P25/28A61K45/06A61K2300/00C07D471/04C07D498/04
Inventor S·纳姆帕利E·加贝利里
Owner AC IMMUNE SA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products